The Proteomics laboratory supports laboratory and clinical research programs by performing mass spectrometry-based analyses of proteins and peptides, for identification, relative quantitative analysis, and post-translational modification (PTM) analysis.

The Metabolomics laboratory enables high-quality metabolomics research by providing advanced mass spectrometry–based analyses, including targeted and untargeted metabolomics and lipidomics, as well as stable isotope tracing to interrogate metabolic flux.

Both groups utilize a range of state-of-the-art equipment and provide a wealth of expertise to their collaborators including extensive data analysis support.

The Bioinformatics Core at Memorial Sloan Kettering Cancer Center provides a wide range of computational services to support researchers with varying expertise in computing. Our services include standard bioinformatics pipelines such as variant calling, RNA-Seq, and single-cell RNA-Seq, along with custom analysis workflows for novel data types. We specialize in advanced areas like spatial proteomics, AI-driven analysis, and developing tools like web apps and databases. Additionally, we offer data management, high-quality graphic generation for publications, and comprehensive support for grant writing. The core also provides training and consulting in computational methods and stays updated with the latest Bioinformatics advancements.

The mission of the GMP compliant Organic Synthesis Core is to provide chemical synthesis services to Center members through a state-of-the art facility staffed by expert professional personnel in chemical synthesis. The Core operates at the interface of chemistry, biology, and medicine, and has the capability of supporting medicinal chemistry efforts to produce and evolve lead candidates and tool compounds in support of Center investigators. The work of the Core has greatly facilitated preclinical studies at the Center. The Core synthesizes novel molecules that are not readily available, either by following described procedures or by developing new and more suitable methods of synthesis.

Core Facility provides functional genomics, high throughput screening (HTS), and high-content screening (HCS) services toward the discovery of novel cancer targets and elucidation of complex, aberrant cellular pathways. Offers assistance and training in range of cloning, customized library design, lentivirus production, assay development, screening, and image analysis considerations to assist researchers in harnessing these powerful target identification tools and drug screening methodologies. Offers CRISPR-mediated transcriptional activation/interference (CRISPRa/CRISPRi) technologies combined with lentivirus delivery systems, customized stable isogenic cell line generation (knockout, HDR-directed knock-in, knockdown, base editing, and prime editing) toward the generation of unique cancer cell line models.

Core supports animal model use in cancer research through teams including Research Animal Resource Center (RARC) and Laboratory of Comparative Pathology (LCP). Animals are employed in the development of new methods for diagnosis and treatment of cancer as well as the elucidation of the basic biological mechanisms resulting in neoplasia. CCMP’s professional and paraprofessional staff (152 FTE) serve as a consultative and technical resource for MSK investigators on all matters related to animal research.

Core provides collaborative process development support to investigators across the Center engaged in new Biotherapeutics initiatives. Core staff are responsible for converting research-lab processes into GMP-compliant manufacturing processes. This includes establishing Standard Operating Procedures (SOPs) and batch records for cell processing, cell engineering, and vector production. Provides full support for cGMP manufacturing of cell products: handling patient cells in cGMP environment, from purification and transduction to expansion and formulation, for use in phase 1 and phase 2 clinical trials. Manufactures vector stocks, oversees biosafety and releases testing of generated projects for human use. This includes analysis of patient cells and vector stocks, assessing characteristics such as phenotype, potency, purity, and stability. Gene transfer and expression analyses are also performed. Core performs analytical post-infusion monitoring. For each trial, the Core develops a comprehensive set of analytical tests to ensure quality and safety of the manufactured drug products.

Biobank and Pathology Core provides resources for human biospecimen-based research to be used to study causes, detection, prevention, and treatment of cancer. Central facility for the collection, processing, storage, and distribution of fresh, frozen, and FFPE-processed human biospecimens (tissues, blood, bone marrow, urine, and other liquid samples) for research use. Core also serves as national resource, as evidenced by the several hundred samples from multiple tumor types that have been provided to the Cancer Genome Atlas (TCGA) and NCI’s CPTAC proteogenomic consortium. Histology Service within the Core facilitates selection of appropriate specimens for tissue analyses and provides the basic services of cutting, dissecting, and staining of fresh-frozen and formalin-fixed, paraffin-embedded tissues. It includes construction of tissue microarray blocks and laser capture microdissection for isolation of pure cell populations and tumor cell enrichment. The Core’s Immunohistochemistry Service provides immunostaining using optimized antibodies for clinico-pathologic research studies.

Core provides support for early discovery and in vivo testing of antitumor detection and therapeutic agents. Provides resources, professional and technical expertise, and advisory services related to evaluation of agents with potential diagnostic or therapeutic activity. ATA Core works closely with investigators to establish preclinical models, including Patient-Derived Xenograft (PDX) and Patient-Derived Organoid (PDO) models, for the design and execution of pharmacokinetic (PK), toxicity, and in vivo efficacy studies. Assists investigators in determining the best formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents.

Core supports MSK investigators who wish to capture self-reported information from culturally diverse patients, caregivers, clinical staff, and community members. The faculty of the PRO-CEL Core are nationally recognized social and behavioral scientists and community engagement experts who provide technical assistance to all users throughout multiple stages of research, including grant and protocol development, research study assistant and support staff training, and result dissemination. Provides methodological support for clinical trial, behavioral, and population-based research that seeks to engage community or minority populations.

Core provides expertise on study design and statistical analysis. Devoted to developing and understanding ways to derive scientific inferences from quantitative data and to developing methods for achieving this aim. The staff are highly trained in this field and experienced in all of the specialized areas of statistical techniques including clinical trials methodology, survival analysis, epidemiologic methods, analysis of genomics data, statistical genetics, methods for diagnostic medicine, health services research, survivorship, evidence-based medicine and psychometric methods.

Core offers suite of animal imaging modalities, including MRI, PET, CT, SPECT, and ultrasound, all commonly used in clinical settings, enhancing the likelihood that findings in animal models will be translatable to human patients. Key instruments include 7.0T and 9.4T MRI systems, PET/MR, PET/CT, SPECT/CT, and advanced ultrasound systems, alongside specialized equipment including a small animal radiation therapy unit and variety of ancillary tools for advanced imaging analysis.

Core facilitates the use of mouse molecular genetics at MSK for in vivo studies of gene functions germane to cancer. Provides expertise in generation and effective use of genetically engineered mouse (GEM) models—namely, molecular and cell biology, embryo micromanipulation, and reproductive biology. Molecular and cellular biology services cover design and assembly of genome engineering reagents, such as donor transgenes and CRISPR/Cas9; performing all aspects of gene targeting in mouse embryonic stem (ES) cells; identification and verification of alleles carried by a generated GEM model; and establishment of new ES cells from a variety of GEM lines. Provides consultation and training for the design and production of GEM models, ES cell culture and manipulation, and mouse reproduction and genetic crosses.

Core is a full-service facility that prepares agents developed by MSK researchers to be used as investigational drugs in preclinical or clinical studies. The Core comprises three principal groups: the Pharmaceutical Product Facility (PPF) for drug formulation/stability and preparation; the Clinical Grade Production (CGP) Facility for bulk product manufacturing, purification, and vialing; and the Pharmacy Investigational Drug Service (PIDS), which develops, procures, prepares, and validates the preparation, packaging, and distribution of investigational drugs for clinical use. Core services include: formulation, analysis, and evaluation of drug release rates; prediction of interactions; and determinations of compatibility and physical stability of medications. Based on the expertise of the RP Core, MSK has been able to bring into early-phase clinical trials multiple types of pharmacologic agents, including traditional small molecules, radiopharmaceuticals, and vaccines.

Core functions include cancer biology, medicine, chemistry, physics, radiochemistry, pharmacology, and engineering. Provides investigators with radionuclides and to incorporate these radionuclides into radiolabeled diagnostic and/or therapeutic pharmaceuticals for both basic research investigations and patient formulations.

The Immune Monitoring Facility (IMF) provides translational research support for immune monitoring during cancer immunotherapy. Robust immune monitoring assays are essential for characterizing the immune status in patients receiving novel immune-modulating therapies, and the insights gained from studying the immune response in treated patients may help transition promising therapies from the clinical trial phase to standard of care. The IMF supports a variety of clinical research activities including standardized processing and cryopreservation of numerous clinical samples on a daily basis from patients on experimental cancer therapies, development and validation of immune monitoring assays, and correlative sample analysis using these assays to evaluate immune responses in patients enrolled in various immunotherapy trials. The facility utilizes highly specialized technologies to analyze both cellular and soluble protein biomarkers with the ultimate goal of identifying biomarkers that correlate with clinical responses which can then guide clinical decisions regarding the patients that may benefit most from specific immunotherapy regimens. Services and assays provided in the facility include, but are not limited to: (1) PBMC and serum/plasma isolation from human whole blood and sample cryopreservation; (2) Multiplex cytokine immunoassays; (3) Immunophenotypic analysis of immune cell subsets by multiparameter flow cytometry; (4) Evaluation of T cell antigen specificity and function by intracellular cytokine staining and ELISPOT assays.

The Stem Cell Research Core stocks, characterizes, and distributes human pluripotent stem cell (hPSC) lines. Performs variety of hPSC-related applications for the stem cell community at SKI and beyond. We are a part of the Starr Foundation-funded Tri-Institutional Stem Cell Initiative that provides shared stem cell expertise and resources among Memorial Sloan Kettering, Weill Cornell, and Rockefeller University.

The Antibody & Bioresource Core Facility supports researchers at both Memorial Sloan Kettering Cancer Center and The Rockefeller University by making it easier for them to:

1.) Develop new monoclonal antibodies that meet their experimental needs through any combination of these services:

... Consultation
... Immunization of mice, rats and Armenian hamsters
... Electrofusion (B cell immortalization / generation of 10,000‘s of hybridoma)
... Isolation of IgG secreting hybridomas, which is 1 - 20% of the hybridomas, for screening to enable a greater number of hybridomas are screened
... ELISA screening
... Cryopreservation and storage of positive cultures
... Subcloning
... Cryopreservation and storage of unscreened fusion products / hybridomas for future screening


2.) Produce monoclonal antibodies

... Conditioned Media
...... 1 to 10 ug monoclonal antibody / ml

... Bioreactor Supernatants:
...... 0.5 to 4 mg monoclonal antibody / ml
...... Purity ranges from 20 to 80%

... Purified monoclonal antibodies:
...... 1 to 10 mg monoclonal antibody / ml
...... Purity > 95%

... Conjugations

... Fragmentation


3.) Mycoplasma Testing


4.) Obtain cell lines developed at Memorial Sloan Kettering Cancer Center and The Rockefeller University


This facility is designed to be both an informational resource as well as a group that provides services for a fee.

Depending upon internal demand, external requests are welcome.

The aim of the Flow Cytometry Core Facility at MSKCC is to provide advanced instrumentation as well as high-level technical and scientific expertise in multi-dimensional Flow Cytometry and Cell Sorting, to facilitate science, improve the quality, and advance the scope of MSK research.

The IGO provides services and expertise to Center investigators interested in evaluating gene expression, chromosome structure, and nucleotide sequence on a broad scale. Enables basic, clinical, and translational research projects across the Center. Through its production group, the Core enables genomic and transcriptomic analyses and has the expertise to process challenging samples from all origins (tissue, dissociated single cells and cell pellets, paraffin curls, blood, serum, etc.). Bulk DNA/RNA assays operate in highly automated environment, from sample reception to sequencing library preparation.

Core delivers specialized histology, microscopy, and cytogenetics services for detection in situ (cells, tissue sections, organoids, and whole mounts) of biomarkers (proteins, glycoproteins, lipids, nucleic acids) and molecular processes in normal and pathological conditions. Performs comprehensive antibody validation on cells and tissues, trains investigators in basic staining principles and assists with experimental assay design and downstream analysis. Core maintains four whole-slide scanners and provides support for quantitative whole-slide analysis. Microscopy and dedicated image analysis staff provide support for simple or complex analysis pipelines.

The Nuclear Magnetic Resonance Core provides analytical services, access and education for analytical instrumentation and related shared scientific resources. Instrumentation includes high field nuclear magnetic resonance, mass spectrometry and optical spectroscopic instruments. Facility offers investigators the ability to monitor chemical reactions, analysis for determination of molecular structure, chemical mechanisms, purity, stability, biological uptake and other properties of chemical compounds.

Core provides expertise, advanced equipment, and leading software to support structural investigations. Core maintains equipment, including Krios cryogenic electron microscopes and computational resources for data collection, processing, and structure determination. These resources include graphical workstations and high-performance Linux cluster, supporting the analysis of large proteins, complexes, and macromolecular assemblies.Core has access to synchrotron beamlines and cryo-EM facilities.Provides training and assistance to users, collaborates with non-structural MSK groups on projects involving macromolecular crystallization and structure determination, offers modeling expertise and guidance, enabling labs to use available structural data in experiment design and interpretation.

We are a team of product development professionals who help institutions and their investigators comply with FDA regulations in the development and manufacturing of investigational products (drugs, biologics, devices) for human clinical trials. Our main work areas are:
- writing quality system documents (e.g., SOPs, Master Batch Records)
- writing IND and IDE applications
- GMP and GLP training programs
- project management for product development
- planning non-clinical studies and placing studies at a CRO
- planning manufacturing and testing programs
- monitoring work at CROs and CMOs
- auditing laboratories and records
- QA review of completed batch records, or of study reports
- planning and management of product stability studies

At our home institution, Memorial Sloan Kettering Cancer Center, we write 5 or more IND applications annually and provide QA services for over 40 manufactured products.

We charge for our work time plus expenses.

A wide range of chromosome analysis techniques are available ranging from basic G-banded karyotyping to FISH -based assays.

We do not handle routine clinical diagnostic samples.